Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer [clinicaltrials:NCT00003652]
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer [clinicaltrials:NCT00003652]
Bio2RDF identifier
NCT00003652
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00003652
identifiers.org URI
anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
RATIONALE: Drugs used i ...... II or stage III anal cancer.
brief title [clinicaltrials_vocabulary:brief-title]
Combination Chemotherapy Plus ...... ge II or Stage III Anal Cancer
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
OBJECTIVES:
- ...... or this study within 4 years.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-01T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
keyword [clinicaltrials_vocabulary:keyword]
basaloid carcinoma of the anus
cloacogenic carcinoma of the anus
squamous cell carcinoma of the anus
stage II anal cancer
stage III anal cancer
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2009-02-06T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00003652
official title [clinicaltrials_vocabulary:official-title]
Intensification Therapy for Lo ...... l - Phase III Intergroup Study
org study id [clinicaltrials_vocabulary:org-study-id]
CDR0000066744
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
secondary id [clinicaltrials_vocabulary:secondary-id]
FNCLCC-FFCD-SFRO-ACCORD-3
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1999-01-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2005-05-01T00:00:00Z
identifier
clinicaltrials:NCT00003652
title
Combination Chemotherapy Plus ...... ge II or Stage III Anal Cancer
@en
type
label
Combination Chemotherapy Plus ...... r [clinicaltrials:NCT00003652]
@en